• About
  • Contact
Thursday, November 19, 2026
The US Inquirer
No Result
View All Result
  • Login
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World
PRICING
SUBSCRIBE
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World
No Result
View All Result
The US Inquirer
No Result
View All Result
Home Politics

2 indicted in connection with counterfeit Ozempic scheme in Florida

by Jacob Rosen
September 29, 2026
Reading Time: 3 mins read
0
2 indicted in connection with counterfeit Ozempic scheme in Florida

RELATED POSTS

Trump praises Putin ahead of rare joint meeting with Xi in China

Musk says he’s “not MAGA,” feels “foolish” about midterm spending

Two Indian nationals have been indicted on conspiracy and smuggling charges related to an international scheme to sell counterfeit Ozempic to U.S. distributors, according to court filings unsealed on Tuesday. 

Swapnadip Roy, 33, and Vicky Ramancha, 37, who are both residents of Dubai and Indian citizens, were indicted in the Middle District of Florida in 2025 for allegedly smuggling counterfeit Ozempic to distributors in the United States at discounted prices. 

Roy and Ramancha allegedly smuggled and sold thousands of counterfeit units of the popular weight-loss drug into the U.S. from unauthorized manufacturers in China, subverting the highly regulated wholesale distribution market in the U.S. that is overseen by the Food and Drug Administration. 

Roy made his initial appearance in federal court on Tuesday after being extradited from Italy to the U.S. Ramancha is still at large. 

Roy and Ramancha are charged with one count of conspiracy to commit smuggling and to defraud the U.S., three counts of smuggling, and two counts of selling counterfeit drugs and holding counterfeit drugs for sale. If convicted, they each face a maximum penalty of 71 years in prison.

The scheme began in July 2023 and continued through April 2024, the Justice Department alleged in the indictment. According to court documents the counterfeit drugs had fake packaging, inserts, labels and needles, all meant to convince individual customers they were purchasing authorized Ozempic, which is manufactured by the Danish pharmaceutical company Novo Nordisk. In December 2023, the FDA warned consumers that a counterfeit version of Ozempic had appeared in the U.S. supply chain. 

The counterfeit units were sold to distributors in the U.S. at discounted prices, and from there would be sold to consumers. The FDA has warned that hazardous counterfeits are on the rise and pose serious health risks. The FDA requires a prescription for GLP-1 drugs.  

According to the indictment, the pair allegedly encouraged companies to ignore compliance concerns, writing in one message that “if you want the product cheap, you have to understand that there are some corners being cut.” Prosecutors also alleged that the pair threatened individuals involved in the distribution scheme.

In March 2024, Ramancha is alleged to have facilitated the delivery of approximately 11,000 units of the fake drug to a warehouse in Ohio. In other instances, thousands of doses were sold or distributed to companies in Florida. 

“Counterfeit prescription drugs — especially common ones — threaten the health and safety of every American who depends on the integrity of our pharmaceutical supply,” Assistant Attorney General A. Tysen Duva of the Justice Department’s Criminal Division said in a statement. “These defendants allegedly exploited people’s health to pay themselves. We will keep pursuing anyone who seeks to deceive American consumers with counterfeit drugs.”  

Lawyers for Roy declined to comment on Tuesday’s proceedings and the charges against their client. 

More from CBS News

Go deeper with The Free Press

In:

Share6Tweet4Share1

Jacob Rosen

Related Posts

Trump praises Putin ahead of rare joint meeting with Xi in China
Politics

Trump praises Putin ahead of rare joint meeting with Xi in China

November 18, 2026
Musk says he’s “not MAGA,” feels “foolish” about midterm spending
Politics

Musk says he’s “not MAGA,” feels “foolish” about midterm spending

November 18, 2026
What to know about Trump’s meeting with Xi in China
Politics

What to know about Trump’s meeting with Xi in China

November 18, 2026
NSA network outage linked to software vulnerability
Politics

NSA network outage linked to software vulnerability

November 18, 2026
Cornyn blocks Trump’s nominee to federal district court in Texas
Politics

Cornyn blocks Trump’s nominee to federal district court in Texas

November 18, 2026
Trump expected to press Xi on Americans detained in China
Politics

Trump expected to press Xi on Americans detained in China

November 18, 2026
Next Post
Trump and major AI executives sign “morally binding” voluntary controls

Trump and major AI executives sign "morally binding" voluntary controls

Trump agrees to let AI leaders police themselves

Trump agrees to let AI leaders police themselves

Recommended Stories

GOP officials divided over Ramaswamy ad with Acton’s mom

GOP officials divided over Ramaswamy ad with Acton’s mom

October 22, 2026
Dems demand tougher standards for companies running Medicaid systems

Dems demand tougher standards for companies running Medicaid systems

October 20, 2026
Ex-staffers claim lack of enforcement, “chaos” under Lutnick

Ex-staffers claim lack of enforcement, “chaos” under Lutnick

November 16, 2026

Popular Stories

  • California’s construction industry hurt by ICE raids, builder says

    California’s construction industry hurt by ICE raids, builder says

    207 shares
    Share 83 Tweet 52
  • Trump decrees any attack on Qatar be treated as threat to U.S.

    37 shares
    Share 15 Tweet 9
  • Supreme Court, in birthright citizenship case, limits use of universal injunctions

    20 shares
    Share 8 Tweet 5
  • Smuggler who used tunnel under U.S.-Mexico border pleads guilty

    16 shares
    Share 6 Tweet 4
  • Poll analysis on cost of living and whether political parties have answers

    16 shares
    Share 6 Tweet 4
The US Inquirer

© 2023 The US Inquirer

Navigate Site

  • Home
  • About
  • Contact
  • Ethics
  • Fact Checking and Corrections Policies
  • Copyright
  • Privacy Policy
  • ISSN: 2832-0522

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • National
  • Politics
  • Business
  • Tech
  • Crime
  • World

© 2023 The US Inquirer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?